- Home
- ABUS vs LAB Comparison
ABUS vs LAB Comparison
Compare ABUS & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- LAB
- Stock Information
- Founded
- ABUS N/A
- LAB 1999
- Country
- ABUS United States
- LAB United States
- Employees
- ABUS N/A
- LAB N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- ABUS Health Care
- LAB Industrials
- Exchange
- ABUS Nasdaq
- LAB Nasdaq
- Market Cap
- ABUS 629.1M
- LAB 562.1M
- IPO Year
- ABUS N/A
- LAB 2011
- Fundamental
- Price
- ABUS $3.21
- LAB $1.88
- Analyst Decision
- ABUS Strong Buy
- LAB Strong Buy
- Analyst Count
- ABUS 4
- LAB 2
- Target Price
- ABUS $5.50
- LAB $2.88
- AVG Volume (30 Days)
- ABUS 876.5K
- LAB 1.7M
- Earning Date
- ABUS 02-27-2025
- LAB 02-26-2025
- Dividend Yield
- ABUS N/A
- LAB N/A
- EPS Growth
- ABUS N/A
- LAB N/A
- EPS
- ABUS N/A
- LAB N/A
- Revenue
- ABUS $6,742,000.00
- LAB $155,902,000.00
- Revenue This Year
- ABUS N/A
- LAB $62.60
- Revenue Next Year
- ABUS N/A
- LAB $9.19
- P/E Ratio
- ABUS N/A
- LAB N/A
- Revenue Growth
- ABUS N/A
- LAB 48.23
- 52 Week Low
- ABUS $2.27
- LAB $1.21
- 52 Week High
- ABUS $4.72
- LAB $3.04
- Technical
- Relative Strength Index (RSI)
- ABUS 43.07
- LAB 51.01
- Support Level
- ABUS $3.16
- LAB $1.67
- Resistance Level
- ABUS $3.38
- LAB $2.14
- Average True Range (ATR)
- ABUS 0.14
- LAB 0.15
- MACD
- ABUS 0.00
- LAB 0.00
- Stochastic Oscillator
- ABUS 19.51
- LAB 52.73
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.